Skip to search formSkip to main contentSkip to account menu

E7820

A small molecule and aromatic sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Old cancer drugs with a modern mechanism.
Cancer Therapy Some cancer drugs are rationally designed on the basis of their known interaction with specific target molecules… 
2014
2014
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor–tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models
Most non‐small‐cell lung cancers (NSCLCs) harboring activating mutations in the epidermal growth factor receptor (EGFR) are… 
2010
2010
Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC).
3537 Background: In vitro,E7820, inhibits α2-integrin expression, endothelial cell proliferation, and vascular tube formation. In… 
2010
2010
26 Is a side effect of molecular targeted therapy a marker of efficacy
2009
2009
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820
SummaryThe aim of this study was to assess the population pharmacokinetics (PopPK) of the novel oral anti-cancer agent E7820… 
2008
2008
A phase I study of E7820 in combination with Cetuximab in patients (pts) with advanced solid tumors
3568 Background: In vitro, E7820 inhibits α2-integrin expression, endothelial cell proliferation and vascular tube formation. The… 
2006
2006
Phase I study of an anti-angiogenic agent with a novel mechanism of action E7820: Safety, pharmacokinetics (PK) and pharmacodynamic (PD) studies in patients (pts) with solid tumors.
3048 Background: E7820 is a first-in-class oral antiangiogenic sulfonamide that inhibits alpha-2 integrin expression, endothelial… 
2005
2005
Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: Results of a phase I study
3082 Background: : E7820 is a first in class orally administered antiangiogenic sulfonamide that inhibits alpha-2 integrin. E7820… 
2004
2004
The anti-angiogenic agent, E7820, induces changes in the architecture of lymphatic vessels around tumors
2004
2004
The anti-angiogenic agent, E7820, induces changes in the architecture of lymphatic vessels around tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)